NYSE:PKI - PerkinElmer Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $86.18 -1.63 (-1.86 %) (As of 10/21/2018 04:00 PM ET)Previous Close$86.18Today's Range$86.11 - $88.5252-Week Range$69.21 - $98.33Volume677,359 shsAverage Volume629,268 shsMarket Capitalization$9.54 billionP/E Ratio26.60Dividend Yield0.32%Beta1 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix and PerkinElmer. The company was founded in 1931 and is headquartered in Waltham, Massachusetts. Receive PKI News and Ratings via Email Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorComputer and Technology SymbolNYSE:PKI CUSIP71404610 Webwww.perkinelmer.com Phone781-663-6900 Debt Debt-to-Equity Ratio0.79 Current Ratio1.69 Quick Ratio1.17 Price-To-Earnings Trailing P/E Ratio26.60 Forward P/E Ratio23.61 P/E Growth1.87 Sales & Book Value Annual Sales$2.26 billion Price / Sales4.23 Cash Flow$3.9244 per share Price / Cash21.96 Book Value$22.71 per share Price / Book3.79 Profitability EPS (Most Recent Fiscal Year)$2.90 Net Income$292.63 million Net Margins5.51% Return on Equity14.25% Return on Assets6.29% Miscellaneous Employees11,000 Outstanding Shares110,730,000Market Cap$9.54 billion PerkinElmer (NYSE:PKI) Frequently Asked Questions What is PerkinElmer's stock symbol? PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI." How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer? PerkinElmer declared a quarterly dividend on Monday, July 23rd. Investors of record on Friday, October 19th will be given a dividend of $0.07 per share on Friday, November 9th. This represents a $0.28 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date is Thursday, October 18th. View PerkinElmer's Dividend History. How were PerkinElmer's earnings last quarter? PerkinElmer, Inc. (NYSE:PKI) posted its quarterly earnings data on Wednesday, August, 1st. The medical research company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.86 by $0.05. The medical research company earned $703.55 million during the quarter, compared to analyst estimates of $694.70 million. PerkinElmer had a net margin of 5.51% and a return on equity of 14.25%. The company's quarterly revenue was up 28.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 earnings per share. View PerkinElmer's Earnings History. When is PerkinElmer's next earnings date? PerkinElmer is scheduled to release their next quarterly earnings announcement on Wednesday, October 31st 2018. View Earnings Estimates for PerkinElmer. What guidance has PerkinElmer issued on next quarter's earnings? PerkinElmer issued an update on its FY18 earnings guidance on Wednesday, August, 1st. The company provided EPS guidance of approx $3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.61. What price target have analysts set for PKI? 10 equities research analysts have issued twelve-month price targets for PerkinElmer's stock. Their predictions range from $73.36 to $100.00. On average, they anticipate PerkinElmer's share price to reach $88.1511 in the next twelve months. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Price Targets for PerkinElmer. What is the consensus analysts' recommendation for PerkinElmer? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer. Who are some of PerkinElmer's key competitors? Some companies that are related to PerkinElmer include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Bruker (BRKR), Coherent (COHR), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO) and Arrayit (ARYC). Who are PerkinElmer's key executives? PerkinElmer's management team includes the folowing people: Mr. Robert F. Friel, Chairman, CEO & Pres (Age 62)Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 49)Mr. James Corbett, Exec. VP & Pres of Discovery and Analytical Solutions (Age 55)Mr. Prahlad R. Singh, Exec. VP & Pres of Diagnostics (Age 53)Mr. James M. Mock, Sr. VP & CFO Who are PerkinElmer's major shareholders? PerkinElmer's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Steigerwald Gordon & Koch Inc. (0.13%), Bank of Montreal Can (0.09%), Aperio Group LLC (0.05%), State of Alaska Department of Revenue (0.02%), Tributary Capital Management LLC (0.01%) and Tributary Capital Management LLC (0.01%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh, Robert F Friel and Vicki L Sato. View Institutional Ownership Trends for PerkinElmer. Which major investors are selling PerkinElmer stock? PKI stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Steigerwald Gordon & Koch Inc., Tributary Capital Management LLC, State of Alaska Department of Revenue and Strs Ohio. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Robert F Friel. View Insider Buying and Selling for PerkinElmer. Which major investors are buying PerkinElmer stock? PKI stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fox Run Management L.L.C., Ipswich Investment Management Co. Inc., First Hawaiian Bank, Aperio Group LLC and Kohmann Bosshard Financial Services LLC. View Insider Buying and Selling for PerkinElmer. How do I buy shares of PerkinElmer? Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is PerkinElmer's stock price today? One share of PKI stock can currently be purchased for approximately $86.18. How big of a company is PerkinElmer? PerkinElmer has a market capitalization of $9.54 billion and generates $2.26 billion in revenue each year. The medical research company earns $292.63 million in net income (profit) each year or $2.90 on an earnings per share basis. PerkinElmer employs 11,000 workers across the globe. What is PerkinElmer's official website? The official website for PerkinElmer is http://www.perkinelmer.com. How can I contact PerkinElmer? PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected] MarketBeat Community Rating for PerkinElmer (NYSE PKI)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 390 (Vote Outperform)Underperform Votes: 400 (Vote Underperform)Total Votes: 790MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/21/2018 by MarketBeat.com StaffFeatured Article: Why do company’s buyback their stock?